Exagen Inc. (XGN) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While XGN currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.92) and Max Pain ($9.14) forces dealer call-delta covering toward $12.52.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Exagen Inc. (XGN) surged +3.57% to $8.70, trading at 65% of its 52-week range ($2.59 – $11.92). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the follo
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the mark
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Exagen Inc. (XGN) ranks #921 by composite RQD confidence (31/100, grade E) and #567 by equity capitalization ($210.8M). Within this direct 5-issuer industry benchmark cohort, XGN leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. BDSX currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with XGN at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XGN
ACTIVE
Exagen Inc. | E | 31/100 | — | 58.3% | -35.0% | +3.57% | $210.8M | Benchmark Subject |
| TLSI TriSalus Life Sciences Inc. | E | 34/100 | — | 84.6% | -35.0% | -1.78% | $237.7M | /tlsi-vs-xgn → |
| BDSX Biodesix Inc. | D | 44/100 | — | — | -35.0% | +8.14% | $260.8M | /bdsx-vs-xgn → |
| BNR Burning Rock Biotech Limited | E | 23/100 | — | 74.7% | -35.0% | -9.87% | $116.5M | /bnr-vs-xgn → |
| YDES YD Bio Limited | D- | 37/100 | — | 28.1% | -20.0% | -6.53% | $415.8M | /ydes-vs-xgn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Exagen Inc. (XGN) reported GAAP revenue of $66.6M (+19.7% vs. FY2024 revenue of $55.6M , and +26.7% cumulative change since FY2023) , GAAP net income of -$20.0M, operating cash flow of -$13.6M, and free cash flow of -$14.3M (-3.4% YoY). On the balance sheet, XGN closed FY2025 with $58.0M in total assets against $22.3M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $66.6M | -$20.0M | -$13.6M | -$14.3M | $58.0M | $22.3M |
| FY2024 (FY) | 2024-12-31 | $55.6M | -$15.1M | -$13.3M | -$13.8M | $44.7M | $19.8M |
| FY2023 (FY) | 2023-12-31 | $52.5M | -$23.7M | -$14.5M | -$14.5M | — | — |
As of 2026-11-01, Exagen Inc. (NASDAQ: XGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $8.70 (+3.57% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XGN ranks #921 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), XGN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $237.7M) and BDSX (Biodesix Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, XGN leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
Per XGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001274737), Exagen Inc. generated $66.6M in revenue (+19.7% YoY), -$20.0M in net income, and -$14.3M in free cash flow against $58.0M in total assets and $22.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XGN last traded at $8.70 (+3.57% on volume of 378,382 shares), positioning the stock +9.85% above its 50-day simple moving average ($7.92) and +72.96% above its 200-day simple moving average ($5.03). Across its 52-week range of $2.59 to $11.92, XGN sits at the 65.5% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.61 to $9.79).
Why XGN Stock surged +3.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.